311 related articles for article (PubMed ID: 23585411)
1. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent.
Wijaya I; Hasan I
Acta Med Indones; 2013 Jan; 45(1):61-6. PubMed ID: 23585411
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
5. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
6. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression and HBV reactivation.
Shouval D; Shibolet O
Semin Liver Dis; 2013 May; 33(2):167-77. PubMed ID: 23749673
[TBL] [Abstract][Full Text] [Related]
8. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.
Xunrong L; Yan AW; Liang R; Lau GK
Rev Med Virol; 2001; 11(5):287-99. PubMed ID: 11590667
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
12. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients].
von Wagner M; Zeuzem S
Dtsch Med Wochenschr; 2009 Feb; 134(6):255-8. PubMed ID: 19180418
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.
Mindikoglu AL; Regev A; Schiff ER
Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1076-81. PubMed ID: 16861051
[TBL] [Abstract][Full Text] [Related]
15. Management of acute hepatitis B and reactivation of hepatitis B.
Jindal A; Kumar M; Sarin SK
Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
[TBL] [Abstract][Full Text] [Related]
16. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
17. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
18. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?
Ekpanyapong S; Reddy KR
Clin Liver Dis; 2020 Aug; 24(3):317-333. PubMed ID: 32620274
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
